|
Video: What is a Stock Split?
|
|
Marker Therapeutics is a clinical-stage immuno-oncology company engaging in the development and commercialization of T cell-based immunotherapies and peptide-based vaccines. Co. is developing three product candidates, including: autologous treatment of lymphoma, and selected solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia (AML); and off-the-shelf products in various indications. Co.'s clinical development programs are: MT-401, which is for the treatment of post-transplant AML; MT-401-OTS, which is for the treatment of AML; MT-601, which is for the treatment of pancreatic cancer; and MT-601, which is for the treatment of lymphoma. According to our MRKR split history records, Marker Therapeutics has had 1 split. | |
|
Marker Therapeutics (MRKR) has 1 split in our MRKR split history database. The split for MRKR took place on January 27, 2023. This was a 1 for 10 reverse split, meaning for each 10 shares of MRKR owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as Marker Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the MRKR split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Marker Therapeutics shares, starting with a $10,000 purchase of MRKR, presented on a split-history-adjusted basis factoring in the complete MRKR split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/01/2014 |
|
End date: |
04/29/2024 |
|
Start price/share: |
$32.20 |
|
End price/share: |
$4.12 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-87.20% |
|
Average Annual Total Return: |
-18.58% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,279.58 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
01/27/2023 | 1 for 10 |
|
|